NGF-mediated alteration of NF-kappaB binding activity after partial immunolesions to rat cholinergic basal forebrain neurons.
There are age-associated cognitive and cholinergic deficits in the neurotrophin-dependent cholinergic basal forebrain neurons (CBFNs). There are also increases in the activity of the transcription factor NF-kappaB in the aged rodent brain that may reflect chronic enhancement of stress response signaling. We used partial immunolesions (PIL) to CBFN to examine the role of endogenous NGF on choline acetyltransferase (ChAT) activity and NGF-mediated NF-kappaB alteration after cholinergic deafferentation. We injected 192 IgG-saporin, an immunotoxin selectively taken up by neurotrophin receptor p75(NTR)-bearing neurons, into lateral ventricles, followed by infusions of anti-NGF to assess NF-kappaB, ChAT and NGF responses to PIL after anti-NGF infusion. Treatment with anti-NGF decreased ChAT activity by 17-34% in the cortex, hippocampus, and olfactory bulb and PIL decreased ChAT activity by 47-73%. Changes in AChE activity levels paralleled those observed for ChAT after PIL. NGF protein levels in the olfactory bulb, but not the cortex or hippocampus, increased significantly after PIL treatment. Infusion of anti-NGF abolished the PIL-induced eight-fold NGF increase in CNS. NF-kappaB binding activity to the IgG-kappaB and ChAT specific NF-kappaB consensus sequences, increased in the cortex but not hippocampus after PIL followed by anti-NGF infusion. It is likely that immunolesion-induced changes in ambient NGF levels may perturb NF-kappaB activity.
Gu
Z
Z
Department of Human Biological Chemistry and Genetics, The University of Texas Medical Branch at Galveston, 301 University Blvd, Galveston, TX, USA.
Toliver-Kinsky
T
T
Glasgow
J
J
Werrbach-Perez
K
K
Perez-Polo
J R
JR
D000110:Acetylcholinesterase / Q000378:metabolism; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D015415:Biomarkers; D002795:Choline O-Acetyltransferase / Q000378:metabolism*; D018678:Cholinergic Agents / Q000494:pharmacology; D004268:DNA-Binding Proteins / Q000378:metabolism; D003714:Denervation; D004586:Electrophoresis; D000922:Immunotoxins / Q000494:pharmacology; D008845:Microinjections; D009699:N-Glycosyl Hydrolases; D016328:NF-kappa B / Q000378:metabolism*; D020932:Nerve Growth Factor / Q000276:immunology / Q000378:metabolism*; D009474:Neurons / Q000201:enzymology*; D016548:Prosencephalon / Q000166:cytology; D011485:Protein Binding / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins
C085696:192 IgG-saporin; D000911:Antibodies, Monoclonal; D015415:Biomarkers; D018678:Cholinergic Agents; D004268:DNA-Binding Proteins; D000922:Immunotoxins; D016328:NF-kappa B; D054789:Ribosome Inactivating Proteins, Type 1; D020932:Nerve Growth Factor; D002795:Choline O-Acetyltransferase; D000110:Acetylcholinesterase; D009699:N-Glycosyl Hydrolases; D000076985:Saporins